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The traditional role of iron chelation therapy has been to reduce body iron burden via
chelation of excess metal from organs and fluids and its excretion via biliary-fecal and/or
urinary routes. In their present use for hemosiderosis, chelation regimens might not be
suitable for treating disorders of iron maldistribution, as those are characterized by toxic
islands of siderosis appearing in a background of normal or subnormal iron levels (e.g.,
sideroblastic anemias, neuro- and cardio-siderosis in Friedreich ataxia- and neurosiderosis
in Parkinson’s disease). We aimed at clearing local siderosis from aberrant labile metal
that promotes oxidative damage, without interfering with essential local functions or with
hematological iron-associated properties. For this purpose we introduced a conservative
mode of iron chelation of dual activity, one based on scavenging labile metal but also
redeploying it to cell acceptors or to physiological transferrin. The “scavenging and
redeployment” mode of action was designed both for correcting aberrant iron distribution
and also for minimizing/preventing systemic loss of chelated metal. We first examine
cell models that recapitulate iron maldistribution and associated dysfunctions identified
with Friedreich ataxia and Parkinson’s disease and use them to explore the ability of the
double-acting agent deferiprone, an orally active chelator, to mediate iron scavenging and
redeployment and thereby causing functional improvement. We subsequently evaluate
the concept in translational models of disease and finally assess its therapeutic potential in
prospective double-blind pilot clinical trials. We claim that any chelator applied to diseases
of regional siderosis, cardiac, neuronal or endocrine ought to preserve both systemic and
regional iron levels. The proposed deferiprone-based therapy has provided a paradigm
for treating regional types of siderosis without affecting hematological parameters and
systemic functions.
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INTRODUCTION
Iron homeostasis relies on the orchestration of a network of
systemic and cellular mechanisms for the acquisition, internal dis-
tribution and use of iron (Cairo and Recalcati, 2007; Camaschella,
2009; Fleming and Ponka, 2012). Disruption of links in the
metabolic network can lead to excessive iron accumulation in par-
ticular cell compartments or tissues (causing localized siderosis
and thus damage) and also to impaired reuse of iron, generating a
“deficiency in the midst of abundance” or vice versa (Breuer and
Cabantchik, 2009; Rouault, 2012, 2013). This impairment trans-
lates into acquired or inherited anaemias (Camaschella, 2009;
Fleming and Ponka, 2012; Rouault, 2012)and other disorders that
display regional siderosis in organs such as heart, (Wood, 2007;
Pennell et al., 2011; Fleming and Ponka, 2012; Rouault, 2012)
brain (Berg et al., 2002; Zecca et al., 2004; Benarroch, 2009; Li
et al., 2011; Sian-Hulsmann et al., 2011; Rouault, 2013)and other
tissues(Pietrangelo, 2007). In all these disorders, the simultaneous
dearth and surplus of iron pose new challenges in drug therapy,
with the need to (i) detoxify discrete siderotic foci without affect-
ing essential iron-dependent functions elsewhere and, conversely,
(ii) replenish iron-deprived regions without further overloading
those already in surplus. Ultimately, addressing the upstream fac-
tors that lead to iron maldistribution might lead to more effective
therapies than those attempting to correct end-organ dysfunc-
tions. (Camaschella, 2013) However, current tools for clinical
intervention are limited to agents designed to treat systemic
siderosis (Berdoukas et al., 2011; Ma et al., 2012; Camaschella,
2013) or iron deficiency (Weiss and Goodnough, 2005) but not
discrete islands of siderosis that appear in a background of nor-
mal or subnormal iron levels (Pietrangelo, 2007; Breuer and
Cabantchik, 2009).
We describe here a novel chelation concept designed to
scavenge excess iron from regional foci of siderosis but also
render the chelated metal metabolically reusable by redeploy-
ing it to cellular machineries or systemic acceptors such as
transferrin.
www.frontiersin.org December 2013 | Volume 4 | Article 167 | 1
Cabantchik et al. Iron chelation of regional siderosis
IRON CHELATION FOR THE TREATMENT OF SYSTEMIC
SIDEROSIS
CAUSES OF TISSUE SIDEROSIS AND TREATMENT
This branch of pharmacology and medicinal chemistry has tra-
ditionally focused on the design, synthesis and application of
drugs for relieving multi-organ iron accumulation (Fleming and
Ponka, 2012) - particularly in patients with primary or sec-
ondary hemosiderosis (Figure 1) (Ma et al., 2012; Camaschella,
2013). In this context, excessive iron accumulation results from
(i) enhanced erythrophagocytosis [which leads to increased iron
deposition in hepatic and splenic reticuloendothelial system
(RES) cells] (Weiss and Goodnough, 2005; Cairo and Recalcati,
2007; Fleming and Ponka, 2012) and/or (ii) the excessive release of
iron into plasma by iron-rich RES cells or by an hyperabsorptive
gut, resulting in high plasma iron levels to override transferrin’s
iron binding capacity (TIBC) and prompting the generation of
non-physiological, non-transferrin-bound iron (NTBI) (Brissot
et al., 2012; Cabantchik et al., 2013). Ultimately, chemically labile
forms of plasma NTBI (referred to generically as labile plasma
iron, LPI) infiltrate cells and attain therein toxic levels (Brissot
et al., 2012; Cabantchik et al., 2013). (Comment: the term NTBI
should be used with caution, as generically it is an apophasis-from
the Greek απóϕασις-, namely something that is defined by what
it is not).
In hemosiderosis, the toxicity that is associated with iron
depends on a numbers of factors: (i) the chemical forms and con-
centrations of the NTBI/LPI, (ii) the LPI’s membrane agencies
and entry routes in particular cells; (iii) the cell’s ability to handle
“surplus” iron by sequestering it within “safe” ferritin sanctu-
aries and (iv) the cell’s enzymatic and non-enzymatic means of
counteracting the metal-catalyzed formation of reactive oxygen
species (ROSs) involved in oxidative damage(Halliwell, 2006).
Although excessive iron ingress into cells can be deleterious, it is
not the hyper-accumulated metal that is causatively associated with
oxidative damage but rather a minor fraction referred to as labile
cell iron (LCI)(Halliwell, 2006; Cabantchik et al., 2013). The LCI
is characterized by the: (i) redox activity, which largely determines
not only its bio-catalytic roles but also its propensity to generate
noxious ROSs from reactive oxygen intermediates of the respi-
ratory chain and other oxygen-dependent reactions; (ii) ability
to transfer the metal between natural ligands (including putative
chaperons) and between compartments, which in turn deter-
mines the intracellular metal distribution, and (iii) the metal’s
amenability to chelation therapy via sequestration into a stable
and potentially unreactive iron-chelates. Both LCI and LPI are
direct pharmacological targets of chelators that act directly on
plasma NTBI-LPI (Cabantchik et al., 2013) and/or permeate into
cells and dissipate intracellular iron agglomerates (De Domenico
et al., 2008).
In all forms of hemosiderosis, the therapeutic challenge is to
attain a balance between iron detoxification and the maintenance
of essential, iron-dependent functions. That requires the moni-
toring of indicators of systemic iron status in the plasma and of
regional iron status in selected organs. Historically, (Pietrangelo,
2007; Berdoukas et al., 2011) the diagnosis and treatment of
hemosiderosis were followed by (i) direct analysis of liver iron
concentration in biopsies taken from what is the major iron
FIGURE 1 | Chelation modalities as treatments for siderosis. Systemic
siderosis (e.g., hemosiderosis) is characterized by elevated plasma iron
levels (hyperferremia) that leads to organ iron accumulation and is generally
characterized by elevated plasma ferritin (i.e., hyperferritinemia) that other
than in a context of inflammation reflects iron stores. Chelation is designed
to detoxify organs from surplus iron and dispose the latter via biliary or
urinary secretion. Regional siderosis covers a wide spectrum of
inherited disorders (e.g., Friedreich ataxia, sideroblastic anemias,
iron-refractory-iron-deficiency anemia-IRIDA), and acquired disorders (e.g.,
anemia of chronic disease-ACD or cancer) that are characterized by a
maldistribution of iron within cells of particular organs (e.g., cardiomyocytes
or neurons or blast cells) or at the level of the organism (e.g., liver and
spleen versus plasma). The plasma iron levels can span from subnormal (as
in functional iron deficient anemias) to supranormal (as in sideroblastic
anemias) and likewise those of plasma (or serum) ferritin levels. Chelation is
designed here not merely to detoxify a siderotic region but where
applicable render the chelated iron available for reuse. The new chelation
modalities comprise (i) targeted detoxification, whereby a prochelator is
activated at the target site by specific resident activators, as found in some
brain areas (Sohn et al., 2008; Zheng et al., 2009) and (ii) iron redeployment,
whereby a chelator that detoxifies cells from surplus iron and/or also
scavenges essential iron reintegrates the metal into the erythron or specific
tissues (Breuer and Cabantchik, 2009; Sohn et al., 2011).
storage organ and (ii) assays of serum levels of ferritin, which (in
the absence of inflammation) is a surrogate (long-term)marker of
liver-accumulated metal. Analytical methods for estimating uri-
nary and fecal iron secretion have been applied in studies of body
iron balance, with a view to directly assessing the efficacy of chela-
tors in reducing the body’s iron burden. (Berdoukas et al., 2011)
The introduction of non-invasive methods for assessing tissue
iron agglomerates was a major step forward in assessing long-
term organ siderosis and the efficacy of iron chelation therapy.
(Berdoukas et al., 2011) These assessments were initially per-
formed in organs such as the liver [by using superconducting
quantum interference device (SQUID)magnetometry] and, more
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recently, in the liver, heart and endocrine glands with T2 and
T2∗ nuclear magnetic resonance (NMR) spin relaxation meth-
ods (Wood, 2007; Berdoukas et al., 2011; Pennell et al., 2011;
Camaschella, 2013). The most prominent example is the case of
cardiac siderosis that results from transfusional hemosiderosis,
in which the T2∗ NMR relaxation time was validated (i) retro-
spectively for its correlation with cardiac iron measured in tissue
biopsies and (ii) prospectively for its correlation with impaired
cardiac function (Wood, 2007; Pennell et al., 2011).
Today’s arsenal of iron chelators in clinical use comprises three
agents approved for the treatment of transfusional hemosidero-
sis, (Berdoukas et al., 2011; Ma et al., 2012; Camaschella, 2013).
The parenterally administered hexadentate deferrioxamine and
the two orally active, bidentate deferiprone (DFP) and the triden-
tate deferasirox (DFX). These agents are used either alone or in
various combinations designed to optimize the reduction of the
body’s iron burden by extracting excess iron from fluids and tis-
sues and with time maintain NTBI-LPI at basal (i.e., sub-toxic)
levels. (Berdoukas et al., 2011; Cabantchik et al., 2013).
IRON CHELATION FOR THE TREATMENT OF REGIONAL
SIDEROSIS
CAUSES AND TARGETS FOR TREATMENT
Unlike hemosiderosis (in which plasma iron infiltrates cells in
several different organs), regional siderosis mostly results from
a disruption in cell homeostasis that causes iron to be abnor-
mally distributed in certain cell types or specific organs (Fleming
and Ponka, 2012; Rouault, 2012). In various types of sideroblastic
anemia (Camaschella, 2009; Fleming and Ponka, 2012; Rouault,
2012) iron accumulates in mitochondria due to faulty use of the
metal in the synthesis or secretion of iron sulfur clusters (ISCs) or
heme (Rouault, 2012, 2013). A concomitant cytosolic iron deple-
tion (Kakhlon et al., 2008; Rouault, 2012) generates a vicious cycle
in which ever more incoming iron ends up in mitochondrial iron
precipitates (Kakhlon et al., 2010;Whitnall et al., 2012). The dam-
age caused by abnormal intracellular metal distribution has two
major components: (i) toxicmitochondrial iron accumulation per
se (mostly as labile/toxic iron-oxides) and (ii) a metabolic decline
in cell iron-dependent activities (due to faulty synthesis of essen-
tial hemoproteins or ISC proteins) (Kakhlon et al., 2008; Rouault,
2012). Abnormal iron distribution is also observed in systemic
functional iron deficiencies (Camaschella, 2009; Fleming and
Ponka, 2012; Rouault, 2012). In acquired anemia of chronic dis-
ease (ACD) (Weiss and Goodnough, 2005) and in inherited iron-
refractory-iron-deficiency-anemia (IRIDA), (Camaschella, 2009;
Fleming and Ponka, 2012) macrophages of the RES system (in
the spleen and liver) accumulate iron. The end results is plasma
iron depletion and ensuing systemic iron deprivation. Moreover,
in patients with chronic kidney disease and functional iron defi-
ciency, intensive treatment with intravenous iron supplements
can also cause the iatrogenic accumulation of macromolecular
iron-sugar aggregates in spleen and liver. This can also be iden-
tified by T2∗ NMR as iron overload (Ghoti et al., 2012). However,
iron accumulation in the RES is per se not pathological, since
apparently no labile iron is generated as long as the metal is safely
shielded within shells of protein (e.g., ferritin) or saccharide (e.g.,
sucrose or dextran).
Iron maldistribution is also found in various neurodegen-
erative disorders(Zecca et al., 2004; Weinreb et al., 2010; Li
et al., 2011; Pichler et al., 2013; Rouault, 2013).In the inher-
ited movement disorder Friedreich’s ataxia (FRDA), siderosis
manifests itself first in the brain’s dentate nuclei and ultimately
in the heart (Rouault, 2013). In Parkinson’s disease (PD), the
dopaminergic neurons of the substantia nigra pars compacta
progressively succumb to oxidative stress (Zecca et al., 2004;
Halliwell, 2006; Li et al., 2011; Sian-Hulsmann et al., 2011;
Pichler et al., 2013).
However, the contribution of brain siderosis to the etiology
of PD is subject to debate—largely because opposing hypotheses
have mostly relied on correlations between functional or bio-
physical indices of PD and indicators of systemic, rather than
local and/or labile, iron levels (Zecca et al., 2004; Hider et al.,
2011; Li et al., 2011) Those studies included trials of chela-
tors that affect systemic iron but not necessarily brain iron, (Li
et al., 2011; Mounsey and Teismann, 2012) or genetic factors
that affect systemic iron levels [e.g., HFE and TMPRSS6 gene
mutations (Camaschella, 2009, 2013; Pichler et al., 2013)] that
in turn might be inversely correlated with PD severity (Pichler
et al., 2013) and possibly with iron accumulated in the substan-
tia nigra. Moreover, in regional siderosis (whether inherited or
acquired), detection of iron agglomerates by T2∗ MRI or histo-
chemical staining is not necessarily indicative of an existing or
impending disease state, just as failure to detect regional iron
agglomerates does not rule out an existing or impending disease
state.
By analogy with cardiac siderosis, we hypothesized that a
causal relationship between iron and disease would be revealed
if the course of disease is modified by selectively modifying labile
iron levels in regions of siderotic damage (Breuer and Cabantchik,
2009; Kakhlon et al., 2010) We further reasoned that removal of
the toxic labile component by “selective” chelation might suffice
for relieving iron maldistribution disorders in which siderosis is
the major pathological factor (i.e., by prevention and/or restora-
tion of otherwise affected functions) (Figure 1). However, for
disorders in which siderosis results from an inherited inabil-
ity to use the metal for the production of essential ISCs or
heme (as in sideroblastic anemia and FRDA), selective detoxifi-
cation by targeted iron chelation (Zheng et al., 2009, 2010) might
have only limited benefits. Moreover, in the absence of a safety
mechanism that keeps chelated iron (resulting from systemic,
non-specific chelation) in the body (Figure 1), the risk of iatro-
genic iron deprivation might outweigh the benefits of regional
detoxification (Breuer and Cabantchik, 2009). And conversely,
the risk that systemic (parenteral) supply of polymeric iron sup-
plements might pose to hypoferremic/ hyperritinemic patients
that retain iron polymers their RES iron stores due to chronic
inflammation for extended time periods (Ghoti et al., 2012)
might outweigh modest changes in erythropoiesis evoked by
increased transferrin saturation (Weiss and Goodnough, 2005).
Prospective studies dealing with those issues are critically miss-
ing not only in clinical practice, but also in validated analy-
sis of chemical stability of iron formulations as part of their
shelf life and especially once delivered to patients via parenteral
routes.
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FIGURE 2 | Iron chelation and redeployment. The redeployment strategy
leans on permeant chelators (CH) (I) that gain access to cells (normal or
Fe-overloaded), (II) chelate labile cell iron and, following egress from cells
into plasma, transfer (III) the chelated Fe to circulating apotransferrin Tf to
form TfFe (IV), which in turn re-deploys the metal to Fe-deficient cells (V) in
a conservative cycle. The various steps in the chelation-redeployment cycle
have been demonstrated preclinically with the bidentate Fe (III) chelator
deferiprone (DFP) (Sohn et al., 2011; Kakhlon et al., 2010; Fleming and
Ponka, 2012). Given that DFP-Fe chelates donate metal to cell or plasma
iron-acceptors (e.g., apo-Tf), the modus operandii of the chelators
resembles siderophores or chaperons that redistribute iron across cells and
their compartments.
NOVEL THERAPEUTIC STRATEGIES FOR REGIONAL
SIDEROSIS
IRON REDEPLOYMENT (FIGURE 2)
This approach seeks to conserve regionally or systemically
chelated iron by redeploying it to sites of use (i.e., to ISC or heme
biosynthetic machineries or the physiological acceptor apotrans-
ferrin) (Sohn et al., 2008; Breuer and Cabantchik, 2009; Kakhlon
et al., 2010). Redeployment (which is essentially applicable to any
disorder of iron maldistribution, whether cellular or systemic)
was initially assessed in cell-based models, (Kakhlon et al., 2008;
Sohn et al., 2008, 2011; Moreau et al., 2013) corroborated in an
animal model of regional siderosis (Moreau et al., 2013; Devos
et al., 2013) and then translated to a clinical setting (Vreugdenhil
et al., 1989; Boddaert et al., 2007; Wood, 2007; Abbruzzese et al.,
2011; Kwiatkowski et al., 2012; Devos et al., 2013; Moreau et al.,
2013). The membrane-permeant, bidentate DFP (1,2-dimethyl-
3-hydroxy-pyridine-4-one) is the prototypic redeployment agent.
It has a moderate ability to (i) rescue iron-overloaded cells by
scavenging labile iron [especially from mitochondria, (Kakhlon
et al., 2008, 2010; Devos et al., 2013; Moreau et al., 2013) the
organelles most affected by cell iron accumulation and the ensu-
ing labile-iron mediated oxidative damage (Halliwell, 2006)] and
(ii) deliver chelated metal to extracellular apotransferrin (Sohn
et al., 2008, 2011) (so that systemic iron losses are essentially
avoided) and (iii) translocate across membranes (including the
blood brain barrier) and gain access to foci of iron accumulation
(thus conferring a degree of protection against metal-initiated
oxidative damage) (Kakhlon et al., 2008; Sohn et al., 2011).
The clinical assessment of DFP as a potential iron redeploy-
ment agent has been facilitated by (i) the drug’s good safety
profile in the treatment of hemosiderosis (Berdoukas et al., 2011)
(ii) its proven chelating (and thus life-saving) effect in patients
with severe cardiac siderosis (Wood, 2007; Berdoukas et al., 2011;
Pennell et al., 2011) and (iii) the ability to support hemoglobin
production in patients with ACD due to rheumatoid arthri-
tis (Vreugdenhil et al., 1989). As a major goal was to redeploy
iron and thus recycle the chelated metal, (Kakhlon et al., 2008;
Breuer and Cabantchik, 2009) dose optimization required the
siderotic region to be monitored for tangible indications of chela-
tion and systemic iron-parameters (via the assessment of plasma
transferrin saturation, complete blood counts and urinary iron)
(Vreugdenhil et al., 1989; Boddaert et al., 2007; Wood, 2007;
Abbruzzese et al., 2011; Kwiatkowski et al., 2012; Devos et al.,
2013; Moreau et al., 2013).
The first attempts to assess the clinical safety and effi-
cacy of up to 12 months of treatment with a moderate
dose of DFP (20–30mg/kg/d, initially combined with the
antioxidant idebenone) were performed in adolescent patients
with FRDA (Boddaert et al., 2007; Velasco-Sánchez et al.,
2011). With the exception of a few cases of neutrope-
nia (which resolved spontaneously after withdrawal of these
patients from the study), DFP treatment modified neither
plasma iron parameters nor the CBC but did reverse the
cardiomyopathic hypertrophy (Velasco-Sánchez et al., 2011).
The observed reduction in R2∗ NMR values in the cere-
bellar dentate nuclei essentially proved that DFP probably
acted in these brain areas by gaining direct access to LCI
and (indirectly) dissipating large iron agglomerates (Boddaert
et al., 2007). Similar hematological responses were observed
following long-term DFP treatment of neurodegeneration with
brain iron accumulation (NBIA) (Abbruzzese et al., 2011;
Kwiatkowski et al., 2012) and, more recently, of PD patients
on stable dopamine/dopaminergic regimens (Moreau et al.,
2013) In the latter population, a 12 month oral DFP regi-
men was associated with clear reductions in the amount of
agglomerated iron in the substantia nigra and attenuation
of disease progression (according to the Unified Parkinson’s
Disease Rating Scale). The drug appeared to act by (i) cell iron
detoxification and thereby a reduction in oxidative damage and
(ii) reduction in enzymatic dopamine catabolism and/or non-
enzymatic oxidation of naturally produced dopamine or admin-
istered dopamine agonists. At this stage we are not in a position
to assess to what extent the protective effects afforded by chela-
tion can be attributed solely to direct chelation of LCI and in
turn reduction of metal-driven oxidations and ensuing cell dam-
age. Chelation of labile iron at the level of prolyl-hydroxylases can
lead to protective mechanisms involving HIF-dependent path-
ways, (Weinreb et al., 2010) particularly those leading to the local
synthesis of erythropoietin, a hormone implicated in neuropro-
tection (Sturm et al., 2010; Matilla-Dueñas et al., 2013).
TARGETED (SITE-DIRECTED) CHELATION (FIGURE 3)
Targeted chelation has the inherent advantage of regional metal
detoxification—particularly when it is based on a chelator that
can be specifically activated in situ in the target region and can
spare the organism from the risk of non-specific chelation and
thus iron deprivation. At present, the best studied experimen-
tal approach is based on pro-chelators that are activated in the
tissue, cell or organelle (i.e., at or close to the site of damage).
This activation is achieved by an intrinsic (local) activation factor
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(e.g., an enzyme) that is only present or active in the target region
(Sohn et al., 2008; Zheng et al., 2009) This concept is exempli-
fied by the carbamylated hydroxyquinoline (HQ) pro-chelators
that are converted by brain cholinesterases (ChEs) into active
HQ chelators. As the ChE enzymes can be chemically modified
and thereby inhibited by the leaving carbamate group (Figure 3),
the approach has the potential benefit of addressing the demen-
tia components of PD and Alzheimer’s disease (AD). Moreover,
the incorporation of N-propargylamine R groups confers to the
HQ prochelators the additional capacity of monoamine oxidase
(MAO) inhibition for the symptomatic treatment of PD (Sohn
et al., 2008; Zheng et al., 2009). Several prochelators with these
single- or double-agent features have been tested in animal mod-
els of neurodegenerative disorders (such as amyotrophic lateral
sclerosis (ALS), AD and PD). They have both neuroprotective
and neurorestorative effects (Sohn et al., 2008; Zheng et al., 2009;
Weinreb et al., 2010) and do not appear to interfere (in the
short term) with systemic iron and other HQ-chelatable biomet-
als (such as copper and zinc). However, remaining to be assessed
is to what extent the MAO-B versus MAO-A selectivity is retained
over the long term treatment of chronic neurodegenerative
condition.
FIGURE 3 | Targeted brain iron detoxification via site-directed chelation.
The rationale is based on carbamate(CM)-blocked hydoxyquinoline (HQ) (I)
susceptibility to cleavage by brain choline esterase (ChE) (Zheng et al., 2009;
Sohn et al., 2011). The chelating unit (II) (depicted in the dotted circle) is
releasedwithin areas of the brain with high ChE levels and is accompanied by
concomitant carbamylation and inhibition of the ChE (CMChE). The HQ
moiety can optionally bemodifiedwith R groups at the indicated positions; for
example, a N-propargyl group can react with and inhibit monoamine oxidase
(MAO), with the release of HQ-acid methylamine and hydrogen peroxide. (III)
and (IV) represent the analogous schemes (I) and (II) as applied to the
hydroxy pyridin-on deferiprone instead of HQ.
CONCLUSIONS AND PERSPECTIVES
Until recently, iron chelation therapy has focused primarily on the
traditional role of reducing total iron burden that characterizes
systemic siderosis (as in hemosiderosis) by chelating excess metal
and excreting it via urinary and/or biliary-fecal routes (Berdoukas
et al., 2011; Brissot et al., 2012; Ma et al., 2012; Camaschella,
2013). In the design of chelators, the major goal of systemic iron
detoxification from excess iron, has hitherto mostly relied on
high binding affinity properties and specificity of the chelating
units for sequestering labile iron but also for generating non-
toxic iron-chelates that ultimately should be disposed from the
organism. The treatment of regional siderosis demanded a novel
modality of chelation, one that can be used for clearing siderotic
regions comprised of labile (toxic) metal but without interfering
with essential local functions, thus sparing the patient’s systemic
iron pools. That selectivity property is of cardinal importance,
since increased serum iron levels have recently been suggested
by genome-wide meta-analysis (GWAS) to be correlated with a
decreased risk of developing PD (Pichler et al., 2013), although,
as we referred earlier, a direct role of the implicated genes (HFE
and TMPRSS) in brain iron metabolism in general and on neu-
rodegeneration in specific, still need to be properly evaluated,
particularly in the context of PD.
The proposed chelation modalities designed for selective treat-
ment of local siderosis have been tested in both cell-based and
animal models. Those modalities are referred as: (i) site-directed
(targeted) chelation, which relies on pro-chelating agents that
are enzymatically converted into active chelators in various brain
areas and act locally as metal-detoxifying agents (Sohn et al.,
2008; Zheng et al., 2009) and (ii) iron redeployment, which aims
at correcting foci of iron maldistribution by reutilizing tissue
chelated metal and thus maintaining it within the body (Breuer
and Cabantchik, 2009; Kakhlon et al., 2010).
Although several novel, brain-targeted pro-chelators have
already displayed neuroprotective and neurorestorative properties
in preclinical models of neurodegeneration, (Sohn et al., 2008;
Zheng et al., 2009; Weinreb et al., 2010) their long-term clinical
safety, specificity and efficacy have yet to be assessed. An iron
redeployment agent that has already shown clinical benefits in
the early stages of degenerative neurosiderosis is DFP, a moder-
ately active, oral chelator with a proven record in the treatment
of transfusional and hereditary cardiac siderosis (Wood, 2007;
Berdoukas et al., 2011; Pennell et al., 2011). To date, most pub-
lished placebo-controlled clinical studies have been carried out
with DFP in combination with either idebenone (in FRDA) or
with dopamine/dopaminergic drugs (in PD). Administration of
the chelator was associated with significant benefits - possibly via
disease-modifying mechanisms. Large, prospective, randomized
clinical trials of DFP (alone and in combination with symp-
tomatic drugs) are now needed, in order to properly appreciate
the full therapeutic potential of new chelation modalities in
regional forms of siderosis. This applies to not only neurosiderosis
(as exemplified by FRDA, NBIA, and PD) but also various forms
of hereditary and acquired sideroblastic anemia (Camaschella,
2009; Fleming and Ponka, 2012; Rouault, 2012) and other hall-
mark iron maldistribution disorders (Pietrangelo, 2007; Kakhlon
et al., 2010; Rouault, 2012). The main challenge is to optimize
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existing treatments and develop novel specific, efficacious and
safer drugs—possibly by combining a site-directed targeting com-
ponent with a chelating moiety that is unmasked at the target sites
and, like DFP, has metal-redeployment features (Figure 3).
AUTHOR CONTRIBUTIONS
Writing of manuscript: a, first draft writing; b, review and criti-
cal comment; c, final draft writing. Zvi Ioav Cabantchik: a, b, c;
Arnold Munnich: b; Moussa B. Youdim: c; David Devos: b,c.
REFERENCES
Abbruzzese, G., Cossu, G., Balocco, M., Marchese, R., Murgia, D., Melis, M., et al.
(2011). A pilot trial of deferiprone for neurodegeneration with brain iron accu-
mulation. Haematologica 96, 1708–1711. doi: 10.3324/haematol.2011.043018
Benarroch, E. E. (2009). Brain iron homeostasis and neurodegenerative disease.
Rev. Neurol. 72, 1437–1440
Berdoukas, B., Farmaki, K., Wood, J. C., and Coates, T. (2011). Iron chelation
in thalassemia: time to reconsider our comfort zones. Expert Rev. Hematol. 4,
17–26. doi: 10.1586/ehm.10.74
Berg, D., Roggendorf, W., Schröder, U., Klein, R., Tatschner, T., Benz, P., et al.
(2002). Echogenicity of the substantia nigra: association with increased iron
content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 59,
999–1005. doi: 10.1001/archneur.59.6.999
Boddaert, N., Le-Quan-Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle,
F., et al. (2007). Selective iron chelation in Friedreich ataxia: biologic and clinical
implications. Blood 110, 401–408. doi: 10.1182/blood-2006-12-065433
Breuer, W., and Cabantchik, Z. I. (2009). Disorders affecting iron distri-
bution: causes, consequences and possible treatments, Blood Med.com;
www.bloodmed.com/800000/mini-reviews1.asp?id=253&p=1&v=1
Brissot, P., Ropert, M., Le Lan, C., and Loréal. O. (2012). Non-transferrin bound
iron: a key role in iron overload and iron toxicity. Rev. Biochim. Biophys. Acta
1820, 403–410. doi: 10.1016/j.bbagen.2011.07.014
Cabantchik, Z. I., Sohn, Y. S., Breuer, W., and Espósito, B. P. (2013). The molec-
ular and cellular basis of iron toxicity in iron overload disorders. Diagn. Ther.
Approaches Rev. Thalassemia Rep. 3, e3. doi: 10.4081/thal.2013.s1.e3
Cairo, G., and Recalcati, S. (2007). Iron-regulatory proteins: molecular biol-
ogy and patho-physiological implications. Exp. Rev. Mol. Med. 9, 1–13. doi:
10.1017/S1462399407000531
Camaschella, C. (2009). Hereditary sideroblastic anemias: pathophysi-
ology, diagnosis, and treatment. Semin. Hematol. 46, 371–377. doi:
10.1053/j.seminhematol.2009.07.001
Camaschella, C. (2013). Treating iron overload. N. Engl. J. Med. 368, 2325–2327.
doi: 10.1056/NEJMcibr1304338
De Domenico, I., McVey Ward, D., and Kaplan, J. (2008). Regulation of iron acqui-
sition and storage: consequences for iron-linked disorders regulation of iron
acquisition and storage: consequences for iron-linked disorders. Nat. Rev. Mol.
Cell Biol. 9, 72–81. doi: 10.1038/nrm2295
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Laloux, C., Jonneaux, A.,
et al. (2013). Targeting chelatable iron as a therapeutic modality in Parkinson’s
disease. Antioxid. Redox Signal. doi: 10.1089/ars.2013.5593. [Epub ahead of
print].
Fleming, R. E., and Ponka, P. (2012). Iron overload in human disease. N. Engl. J.
Med. 66, 348–359. doi: 10.1056/NEJMra1004967
Ghoti, H., Rachmilewitz, E. A., Simon-Lopez, R., Gaber, R., Katzir, Z., Konen,
E., et al. (2012). Evidence for tissue iron overload in long-term hemodialysis
patients and the impact of withdrawing parenteral iron. Eur. J. Haematol. 89,
87–93. doi: 10.1111/j.1600-0609.2012.01783.x
Halliwell, B. (2006). Oxidative stress and neurodegeneration: where are we now?
J. Neurochem. 97, 1634–1658. doi: 10.1111/j.1471-4159.2006.03907.x
Hider, R. C., Roy, S., Ma, Y. M., Le Kong, X., and Preston, J. (2011). The potential
application of iron chelators for the treatment of neurodegenerative diseases.
Metallomics 3, 239–249. doi: 10.1039/c0mt00087f
Kakhlon, O., Breuer, W., Munnich, A., and Cabantchik, Z. I. (2010). Iron relocation
therapy for the treatment of diseases of regional iron accumulation. Rev. Can. J.
Physiol. Pharmacol. 88, 187–196. doi: 10.1139/Y09-128
Kakhlon, O., Manning, H., Breuer, W., Cortopassi, G., Munnich, A., and
Cabantchik, Z. I. (2008). Cell functions impaired by frataxin deficiency
are restored by drug-mediated iron relocation. Blood 112, 5219–5227. doi:
10.1182/blood-2008-06-161919
Kwiatkowski, A., Ryckewaert, G., Jissendi Tchofo, P., Moreau, C., Vuillaume, I.,
Chinnery, P. F., et al. (2012). Long-term improvement under deferiprone in a
case of neurodegeneration with brain iron accumulation. Parkinsonism Relat.
Disord. 18, 110–112. doi: 10.1016/j.parkreldis.2011.06.024
Li, X., Jankovic, J., and Le, W. (2011). Iron chelation and neuroprotection in neu-
rodegenerative diseases. J. Neural. Transm. 118, 473–477. doi: 10.1007/s00702-
010-0518-0
Ma, Y., Zhou, T., Kong, X., and Hider, R. C. (2012). Chelating agents for the treat-
ment of systemic iron overload. Rev. Curr. Med. Chem. 19, 2816–2827. doi:
10.2174/092986712800609724
Matilla-Dueñas, A., Serrano, C., Ivánovic, Y., Alvarez R., Latorre P., and Geni’s,
D. (2013). “Novel therapeutic challenges in cerebellar diseases,” in Handbook
of the cerebellum and cerebellar disorders, eds M. Manto, D.L. Gruol, J.D.
Schmahmann, N. Koibuchi, and F. Rossi (New York, NY; Dordrecht: Springer
Science+Business Media), 2370–2394. doi: 10.1007/978-94-007-1333-8_106
Moreau, C., Devedjian, J. C., Kluza, J., Laloux, C., Jonneaux, A., Ryckewaert,
G. et al. (2013). Targeting brain chelatable iron as a therapeutic strategy
for Parkinson’s disease. Transl. Clin. Stud. Am. J. Hematol. 88, E5–E243. doi:
10.1002/ajh.23453
Mounsey, R. B., and Teismann, P. (2012). Chelators in the treatment
of iron accumulation in Parkinson’s disease. Int. J. Cell Biol. 983245.
doi:10.1155/2012/983245
Pennell, D. J., Carpenter, J. P., Roughton, M., and Cabantchik, Z. (2011). On
improvement in ejection fraction with iron chelation in thalassemia major
and the risk of future heart failure. J. Cardiovasc. Magn. Reson. 13:45. doi:
10.1186/1532-429X-13-45
Pichler, I., Del Greco, M. F., Gögele, M., Lill, C. M., Bertram, L., Do, C. B., et al.
(2013). Serum iron levels and the risk of Parkinson disease: a mendelian ran-
domization study. PLoS Med. 10:e1001462. doi: 10.1371/annotation/c4d81646-
0c0e-4a3e-9425-b220bae2d8b6
Pietrangelo, A. (2007). Iron chelation beyond transfusion iron overload. Am. J.
Hematol. 82, 1142–1146. doi: 10.1002/ajh.21101
Rouault, T. A. (2012). Biogenesis of iron-sulfur clusters in mammalian cells: new
insights and relevance to human disease. Dis. Model Mech. 5, 155–164. doi:
10.1242/dmm.009019
Rouault, T. A. (2013). Iron metabolism in the CNS: implications for neurodegen-
erative diseases. Nat. Rev. Neurosci. 14, 551–564. doi: 10.1038/nrn3453
Sian-Hulsmann, J., Mandel, S., Youdim, M. B., and Riederer, P. (2011). The rel-
evance of iron in the pathogenesis of Parkinson’s disease. J. Neurochem. 118,
939–957. doi: 10.1111/j.1471-4159.2010.07132.x
Sohn, Y. S., Breuer, W., Munnich, A., and Cabantchik, Z. I. (2008). Redistribution
of accumulated cell iron: a modality of chelation with therapeutic implications.
Blood. 111, 1690–1699. doi: 10.1182/blood-2007-07-102335
Sohn, Y. S., Mitterstiller, A. M., Breuer, W., Weiss, G., and Cabantchik, Z. I.
(2011). Rescuing iron overloaded macrophages by conservative relocation
of accumulated metal. Br. J. Pharmacol. 164, 406–418. doi: 10.1111/j.1476-
5381.2010.01120.x
Sturm, B., Helminger, M., Steinkellner, H., Heidari, M. M., Goldenberg, H., and
Scheiber-Mojdehkar, B. (2010). Carbamylated erythropoietin increases frataxin
independent from the erythropoietin receptor. Eur J Clin Invest. 40, 561–565.
doi: 10.1111/j.1365-2362.2010.02292.x
Velasco-Sánchez, D., Aracil, A., Montero, R., Mas, A., Jiménez, L., O’Callaghan, M.,
et al. (2011). Combined therapy with idebenone and deferiprone in patients
with Friedreich’s ataxia. Cerebellum 10, 1–8. doi: 10.1007/s12311-010-0212-7
Vreugdenhil, G., Swaak, A. J., Kontoghiorghes, G. J., and van Eijk, H. G. (1989).
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis
patients. Lancet 8676, 1398–1409. doi: 10.1016/S0140-6736(89)92011-4
Weinreb, O., Amit, T., Mandel, S., Kupershmidt, L., and Youdim, M. B. (2010).
Neuroprotective multifunctional iron chelators: from redox-sensitive process
to novel therapeutic opportunities. Antioxid. Redox Signal. 13, 919–949. doi:
10.1089/ars.2009.2929
Weiss, G., and Goodnough, L. T. (2005). Anemia of chronic disease.N. Engl. J. Med.
352, 1011–1023. doi: 10.1056/NEJMra041809
Whitnall, M., Suryo Rahmanto, Y., Huang, M. L., Saletta, F., Lok, H. C., Gutiérrez,
L. et al. (2012). Identification of nonferritin mitochondrial iron deposits
in a mouse model of Friedreich ataxia. Proc. Natl. Acad. Sci. U.S.A. 109,
20590–20595. doi: 10.1073/pnas.1215349109
Frontiers in Pharmacology | Drug Metabolism and Transport December 2013 | Volume 4 | Article 167 | 6
Cabantchik et al. Iron chelation of regional siderosis
Wood, J. C. (2007). Magnetic resonance imaging measurement of iron overload.
Curr. Opin. Hematol. 14, 183–190. doi: 10.1097/MOH.0b013e3280d2b76b
Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R., and Crichton, R. R. (2004).
Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5,
863–873. doi: 10.1038/nrn1537
Zheng, H., Youdim, M. B., and Fridkin, M. (2009). Site-activated multifunctional
chelator with acetyl-cholinester-ase and neuroprotective-neurorestorative
moieties for Alzheimer’s therapy. J. Med. Chem. 52, 4095–4098. doi:
10.1021/jm900504c
Zheng, H., Youdim, M. B., and Fridkin, M. (2010). Site-activated chelators target-
ing acetyl-cholinesterase and monoamine oxidase for Alzheimer’s therapy. ACS
Chem. Biol. 5, 603–661. doi: 10.1021/cb900264w
Conflict of Interest Statement: The authors have no financial disclosures to
make or potential conflicts of interest to report in relation to this review. (The
clinical trial on PD was funded by the French Ministry of Health PHRC grant
Projet Hospitalier Recherche Clinique Protocol ID: 2008-006842-25), whereas
Apopharma provided the compound deferiprone and instructions on its use.
Zvi Ioav Cabantchik was supported by the A&M Della Pergola Chair in Life
Sciences, served on the Scientific Advisory Board of Novartis ESB, received in
the past research grants from NIH, EEC (5 and 6 framework), Israel Science
Foundation, AFIRNE (Paris), Novartis, Shire and Apopharma (also lecture
honoraria from the last two) and is presently a consultant for Aferrix, Ltd and
Hinoman, Ltd, Israel. David Devos served on the Scientific Advisory Board for
Novartis and Aguettant and has received PHRC grants from the French Ministry
of Health and research funding from the ARSLA charity and honoraria from
pharmaceutical companies for consultancy and lectures. Arnold Munnich is
the head of the Pediatric Genetic Unit at Hospital Necker, Paris France. He has
served as an advisor to Sanofi Genzyme until May 2013. He has presently no
other appointment with commercial entities. Moussa B. Youdim receives Royalties
from Teva Pharmaceutical Co. Israel and is Chief Scientific Officer co-owner and
shareholder of Abital Pharma Pipeline Ltd, Israel, and of Avraham Pharmaceutical
Co. Israel.
Received: 21 November 2013; paper pending published: 09 December 2013; accepted:
15 December 2013; published online: 31 December 2013.
Citation: Cabantchik ZI, Munnich A, Youdim MB and Devos D (2013) Regional
siderosis: a new challenge for iron chelation therapy. Front. Pharmacol. 4:167. doi:
10.3389/fphar.2013.00167
This article was submitted to Drug Metabolism and Transport, a section of the journal
Frontiers in Pharmacology.
Copyright © 2013 Cabantchik, Munnich, Youdim and Devos. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org December 2013 | Volume 4 | Article 167 | 7
